{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Switch&page=9",
    "query": {
      "intervention": "Switch",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 866,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Switch&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Switch&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T10:55:18.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03372369",
      "title": "Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Contraception",
        "Knowledge, Attitudes, Practice"
      ],
      "interventions": [
        {
          "name": "View CDC Poster",
          "type": "OTHER"
        },
        {
          "name": "View Patient-Centered Poster",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "44 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 44 Years · Female only"
      },
      "enrollment_count": 990,
      "start_date": "2018-01-26",
      "completion_date": "2018-02-13",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03372369"
    },
    {
      "nct_id": "NCT03060083",
      "title": "Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)",
          "type": "OTHER"
        },
        {
          "name": "Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2017-02-08",
      "completion_date": "2018-01-10",
      "has_results": true,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03060083"
    },
    {
      "nct_id": "NCT06162663",
      "title": "Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Suvorexant Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2024-09-20",
      "completion_date": "2026-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162663"
    },
    {
      "nct_id": "NCT04564339",
      "title": "Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 123,
      "start_date": "2021-01-19",
      "completion_date": "2025-08-18",
      "has_results": true,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 17,
      "location_summary": "San Dimas, California • Santa Monica, California • South Gate, California + 13 more",
      "locations": [
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "South Gate",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04564339"
    },
    {
      "nct_id": "NCT01742832",
      "title": "Double-Blind Treatment of Major Depressive Disorder With Vilazodone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Vilazodone",
          "type": "DRUG"
        },
        {
          "name": "Citalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 79,
      "start_date": "2013-05",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2023-02-23",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742832"
    },
    {
      "nct_id": "NCT00338949",
      "title": "Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Metabolic Syndrome X",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Switch",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veterans Medical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "2006-06",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00338949"
    },
    {
      "nct_id": "NCT06630299",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-Infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral Combinations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-10-08",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630299"
    },
    {
      "nct_id": "NCT03809663",
      "title": "A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tezepelumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 251,
      "start_date": "2019-03-15",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 16,
      "location_summary": "Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "West Dundee",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809663"
    },
    {
      "nct_id": "NCT06964464",
      "title": "Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction (HFrEF)",
        "Sudden Cardiac Death",
        "Ventricular Arrhythmia",
        "Implantable Cardioverter Defibrillator (ICD)",
        "Beta-blocker Therapy",
        "Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Metoprolol Succinate",
          "type": "DRUG"
        },
        {
          "name": "Carvedilol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2025-08-17",
      "completion_date": "2031-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Rome, Georgia • Shawnee Mission, Kansas + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rome",
          "state": "Georgia"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964464"
    },
    {
      "nct_id": "NCT03251144",
      "title": "Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "Antiviral Toxicity",
        "Antiviral Drug Adverse Reaction",
        "Mitochondrial Alteration"
      ],
      "interventions": [
        {
          "name": "Switch to E/C/FTC/TAF daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2019-04-01",
      "completion_date": "2021-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-10-18T10:55:18.818Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251144"
    }
  ]
}